Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Первый опыт применения алемтузумаба у больных хроническим лимфолейкозом, рефрактерных к флударабинсодержащим программам химиотерапии
Первый опыт применения алемтузумаба у больных хроническим лимфолейкозом, рефрактерных к флударабинсодержащим программам химиотерапии
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Eichhorst BF, Busch R, Stauch M et al. Fludarabine indused higher response rates in fist line therapy of older patients with advanced chronic lymphocytic leukemia than chlorambucil: interim analysis of a phase III study of the German CLL Study Group (GCLLSG). Blood 2003; 102: Abstr. 369.
2. Tothova E, Kafkova A, Fricova M et al. Fludarabine combined with cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukemia. Neoplasma 2003; 50: 433–7.
3. Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–8.
4. Keating M, O'Brien S, Albitar M et al. Early results of chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 2979–1088.
5. Бялик Т.Е., Волкова M.A., Загоскина Т.П. и др. Флударабин в лечении хронического лимфолейкоза: Гематол. и трансфузиол. 2004; 3: 6–11.
6. Eichhorst BF, Bush R, Hopfinger G et al. Fludarabine plus cyclophosphamide (FC) versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–91.
7. Kowal M, Dmoszynska A, Levanovski K et al. Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukemia (B-CLL)-Polish multicentre study. Leuk. Lymphoma 2004; 45: 1159–65.
8. Bosch F, Ferrer A, Lopez-Guillermo A et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976–84.
9. Leporrier M. Role of fludarabine as monotherapy treatment of chronic lymphocytic leukemia. Hematol J 2004; 5: S10–9.
10. Hendry L, Bowen A, Matutes E et al. fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgking's lymphoma. Leuk. Lymphoma 2004; 45: 945–50.
11. Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891–7.
12. Keating MG, Flinn I, Jain V et al. Therapeutic role of alemtusumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–61.
13. O'Brien SM, Kantarjian HM, Thomas DA et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657–63.
14. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87 (12): 4990–7.
15. Moreton P, Kennedy B, Lukas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtusumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23 (13): 2971–9.
16. Pedkins J, Flinn J, Howard R et al. Frequency and type of serious and small lymphocytic lumphoma: implication for clinical trials in this patient population. Cancer 2002; 94: 2033–9.
17. Lundin J, Porwit McDonald A, Rossmann E. Cellular immune reconstitution after subcutaneous alemtusumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukemia (B-CLL). Leukemia 2004; 18: 484–90.
2. Tothova E, Kafkova A, Fricova M et al. Fludarabine combined with cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukemia. Neoplasma 2003; 50: 433–7.
3. Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–8.
4. Keating M, O'Brien S, Albitar M et al. Early results of chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 2979–1088.
5. Бялик Т.Е., Волкова M.A., Загоскина Т.П. и др. Флударабин в лечении хронического лимфолейкоза: Гематол. и трансфузиол. 2004; 3: 6–11.
6. Eichhorst BF, Bush R, Hopfinger G et al. Fludarabine plus cyclophosphamide (FC) versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–91.
7. Kowal M, Dmoszynska A, Levanovski K et al. Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukemia (B-CLL)-Polish multicentre study. Leuk. Lymphoma 2004; 45: 1159–65.
8. Bosch F, Ferrer A, Lopez-Guillermo A et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976–84.
9. Leporrier M. Role of fludarabine as monotherapy treatment of chronic lymphocytic leukemia. Hematol J 2004; 5: S10–9.
10. Hendry L, Bowen A, Matutes E et al. fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgking's lymphoma. Leuk. Lymphoma 2004; 45: 945–50.
11. Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891–7.
12. Keating MG, Flinn I, Jain V et al. Therapeutic role of alemtusumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–61.
13. O'Brien SM, Kantarjian HM, Thomas DA et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657–63.
14. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87 (12): 4990–7.
15. Moreton P, Kennedy B, Lukas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtusumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23 (13): 2971–9.
16. Pedkins J, Flinn J, Howard R et al. Frequency and type of serious and small lymphocytic lumphoma: implication for clinical trials in this patient population. Cancer 2002; 94: 2033–9.
17. Lundin J, Porwit McDonald A, Rossmann E. Cellular immune reconstitution after subcutaneous alemtusumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukemia (B-CLL). Leukemia 2004; 18: 484–90.
Авторы
Т.П.Загоскина, О.В.Малых, М.Н.Хоробрых, В.И.Демьянова, Н.В.Исаева, И.В.Гришина
ФГУ Кировский НИИ гематологии и переливания крови Росмедтехнологий
ФГУ Кировский НИИ гематологии и переливания крови Росмедтехнологий
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.